Ernexa Therapeutics Inc.: Form 10-K for the period ended Dec 31, 2021
Filed with the SEC on Apr 15, 2022 and accepted by EDGAR at Apr 15, 2022, 17:07 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Operating income | 12 months2021-01-01 to 2021-12-31 | −$113.6m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2021-01-01 to 2021-12-31 | $5.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2021-01-01 to 2021-12-31 | −$122.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2021-01-01 to 2021-12-31 | −$2.82 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2021-01-01 to 2021-12-31 | −$2.82 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2021-01-01 to 2021-12-31 | 43,306,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2021-01-01 to 2021-12-31 | −$23.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2021-01-01 to 2021-12-31 | $154.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Current assets | At period end2021-12-31 | $18.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-12-31 | $32.4m | us-gaap:Assets |
| Current liabilities | At period end2021-12-31 | $3.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-12-31 | $25.9m | us-gaap:Liabilities |
| Shareholders' equity | At period end2021-12-31 | $6.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001140361-22-014764. Last ingested by Listed: Nov 6, 2026, 17:52 ET. Listed shows no prices and gives no investment advice.